OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The ever‐increasing importance of cancer as a leading cause of premature death worldwide	1190
Annual report to the nation on the status of cancer, part 1: National cancer statistics	227
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system	177
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma	147
Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities	118
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017	105
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study	97
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach	94
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospectiv	91
Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017	91
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studies	90
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax	88
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis	88
Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years	86
Racial disparities in Black men with prostate cancer: A literature review	85
The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global	81
Impact of the COVID‐19 pandemic on diagnosis of new cancers: A national multicenter study of the Veterans Affairs Healthcare System	74
Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer	69
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial	65
Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial	63
Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors	63
Population‐level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures	62
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies	58
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis	56
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort	55

Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study	55
Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women	53
Loneliness and mental health during the COVID‐19 pandemic in older breast cancer survivors and noncancer controls	53
Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study	52
Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses	50
Health‐related quality of life outcomes among breast cancer survivors	50
What matters most: Randomized controlled trial of breast cancer surgery conversation aids across socioeconomic strata	48
Trajectories of fear of cancer recurrence in young breast cancer survivors	47
Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case‐control study	46
The future of cancer screening after COVID‐19 may be at home	46
Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer	45
Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer	45
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibit	44
Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy	44
High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean	44
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies	44
Loneliness and symptom burden in oncology patients during the COVID‐19 pandemic	43
A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia	43